{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:33:10Z","timestamp":1778923990097,"version":"3.51.4"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Children with metastatic hepatoblastoma have a poor prognosis, even with dose intensification of cisplatin and doxorubicin. Vincristine and irinotecan have demonstrated activity in high risk disease. This report describes a 3-year-old girl with metastatic hepatoblastoma with unresectable disease after 5 cycles of cisplatin, 5-fluorouracil, vincristine, and doxorubicin who had a complete response of her metastatic disease to vincristine and irinotecan (intravenous and oral forms), allowing surgical resection of her liver disease. She remains in remission 48 months since therapy completion.<\/jats:p>","DOI":"10.1097\/mph.0000000000001171","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T19:28:07Z","timestamp":1523993287000},"page":"e171-e173","source":"Crossref","is-referenced-by-count":4,"title":["Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival"],"prefix":"10.1097","volume":"41","author":[{"given":"Jacquelyn M.","family":"Powers","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine"},{"name":"Texas Children\u2019s Hospital, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha M.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Texas Southwestern Medical Center"},{"name":"Children\u2019s Health, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Wickiser","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Texas Southwestern Medical Center"},{"name":"Children\u2019s Health, Dallas, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/pbc.24219","article-title":"Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children\u2019s Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein","year":"2017","journal-title":"Cancer"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HMER.S89997","article-title":"Unresectable hepatoblastoma: current perspectives","volume":"9","author":"Trobaugh-Lotrario","year":"2017","journal-title":"Hepat Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pbc.22407","article-title":"Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children\u2019s Oncology Group phase I consortium study","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatric Blood Cancer"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2017.73.5654","article-title":"Characterization of pulmonary metastases in children with hepatoblastoma treated on Children\u2019s Oncology Group Protocol AHEP0731 (the treatment of children with all stages of hepatoblastoma): a report from the Children\u2019s Oncology Group","volume":"35","author":"O\u2019Neill","year":"2017","journal-title":"J Clin Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma\u2014a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pbc.22408","article-title":"Irinotecan as maintenance therapy in high-risk hepatoblastoma","volume":"54","author":"Qayed","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pbc.24547","article-title":"Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors","volume":"60","author":"Wagner","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1200\/JCO.2010.29.7390","article-title":"Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"28","author":"Mascarenhas","year":"2010","journal-title":"J Clinical Oncol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/pbc.24621","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma","volume":"60","author":"Raciborska","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2008.18.5918","article-title":"Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study","volume":"27","author":"Wagner","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:09:42Z","timestamp":1695013782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001171","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}